Full-Time

Lead – CMC Sterile Drug Product

Confirmed live in the last 24 hours

Amylyx Pharmaceuticals

Amylyx Pharmaceuticals

201-500 employees

Develops treatments for neurodegenerative diseases

Biotechnology
Healthcare

Senior, Expert

Remote in USA

Must reside and work within the United States in a state where Amylyx currently does business.

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Requirements
  • Prior experience with formulation development and sterile drug product process development including process validation, global regulatory requirements, and CMC filings. Prior experience in injectable device or combination products a plus
  • BS in Chemistry, Chemical Engineering, or related field with a minimum of 8 years’ experience supporting sterile drug product formulation and process development and manufacturing; advanced degree in an applicable field desirable
  • Must be able to function independently and influence appropriate stakeholders and recommend scientifically rigorous, phase appropriate, risk-management based solutions to complex technical challenges
  • Advanced knowledge of cGMP/GLP regulations, ICH, FDA CMC Guidance Documents
  • Experience working with contract manufacturing organizations
  • Excellent communication and teamwork skills
  • Ability to travel internationally up to 10%
Responsibilities
  • Technical SME and process owner –develop scalable manufacturing process for synthetic oligonucleotide and peptide drug products.
  • Serve as the CMC Technical Lead including authoring IND and NDA Module 3, Master Batch Records, Validation Plans and Reports, act as the technical lead for regulatory submissions, inspections, and audits.
  • Work with contract manufacturing organizations to develop scalable and robust manufacturing processes for oligonucleotides and peptide products.
  • Provide technical leadership for vendor selection, process transfers and validations.
  • Manage external resources including Consultants and Contractors, as needed to deliver projects.
  • Travel to global manufacturing sites to support operations and validation activities
Amylyx Pharmaceuticals

Amylyx Pharmaceuticals

View

Amylyx Pharmaceuticals develops treatments for neurodegenerative diseases, focusing on conditions like Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's Disease (ALZ). Their main product, AMX0035, is currently undergoing clinical trials, including the CENTAUR ALS trial, which showed significant benefits for ALS patients through a randomized, double-blind, placebo-controlled study. They are also conducting the PEGASUS trial to assess AMX0035's safety and effectiveness for Alzheimer's patients. Unlike many competitors, Amylyx emphasizes community engagement and awareness campaigns, such as ALS Awareness Month, to educate the public and foster support for those affected by these diseases. The company's goal is to bring effective therapies to market that improve patient outcomes.

Company Stage

IPO

Total Funding

$166.7M

Headquarters

Cambridge, Massachusetts

Founded

2013

Growth & Insights
Headcount

6 month growth

-38%

1 year growth

-33%

2 year growth

1%
Simplify Jobs

Simplify's Take

What believers are saying

  • Successful acquisition of Phase 3-ready avexitide from Eiger could diversify Amylyx's pipeline and open new revenue streams.
  • Interim data from the Phase 2 HELIOS trial shows promising results for AMX0035 in treating Wolfram syndrome, indicating potential for broader applications.
  • The appointment of experienced professionals like Dr. Bernhardt Zeiher to the Board of Directors strengthens the company's leadership and strategic direction.

What critics are saying

  • The failure of the Phase III PHOENIX trial and subsequent market withdrawal of Relyvrio raises concerns about the efficacy of Amylyx's treatments.
  • A significant workforce reduction by 70% under a restructuring plan could impact company morale and operational efficiency.

What makes Amylyx Pharmaceuticals unique

  • Amylyx Pharmaceuticals focuses on neurodegenerative diseases like ALS and Alzheimer's, setting it apart from competitors with broader therapeutic areas.
  • The company's flagship product, AMX0035, has shown significant treatment benefits in rigorous clinical trials, including the CENTAUR ALS trial, which is a strong validation of its efficacy.
  • Amylyx's commitment to community engagement and awareness campaigns, such as ALS Awareness Month, enhances its brand and builds a supportive community around its cause.

Help us improve and share your feedback! Did you find this helpful?